What is Avalon Globocare?
Avalon Globocare Corp. operates at the intersection of biotechnology and digital health, functioning as a multifaceted enterprise. The company is recognized for its commitment to developing innovative precision diagnostics and consumer-centric health solutions, such as the KetoAir breathalyzer. Beyond its core diagnostic offerings, Avalon has aggressively expanded into the AI sector, leveraging its subsidiary to deploy sophisticated video analytics and machine learning platforms. By integrating these disparate technologies, the firm aims to streamline healthcare delivery and improve patient outcomes through data-driven insights. Its business model is characterized by a robust pipeline of proprietary technologies and strategic partnerships that facilitate the commercialization of its research and development efforts.
How much funding has Avalon Globocare raised?
Avalon Globocare has raised a total of $22.8M across 2 funding rounds:
Other Financing Round
$20M
Stock/Share Issuance
$2.8M
Other Financing Round (2019): $20M with participation from Daniel Lu
Stock/Share Issuance (2026): $2.8M, investors not publicly disclosed
Key Investors in Avalon Globocare
Daniel Lu
An individual investor with a focus on high-growth biotechnology and healthcare technology ventures.
Undisclosed Investor
An undisclosed investor participating in the funding round, likely representing a strategic institutional partner.
What's next for Avalon Globocare?
With the recent infusion of $2.8M, Avalon Globocare is well-positioned to accelerate its enterprise-level growth strategy. The company is expected to prioritize the scaling of its AI-driven diagnostic platforms, which serve as a cornerstone for its long-term competitive advantage. Furthermore, the capital will likely support the expansion of its consumer health division, allowing for broader market penetration of its existing product suite. As the firm transitions into its next phase of development, stakeholders will be monitoring its ability to integrate new AI capabilities into its diagnostic workflows, potentially setting a new standard for precision medicine. The strategic deployment of these funds will be critical in maintaining the company's momentum within the highly competitive biotechnology landscape.
See full Avalon Globocare company page
